[SCHEDULE 13G/A] Sharps Technology Inc. Warrant SEC Filing

Rhea-AI Filing Summary

Altium Capital Management LLC, Altium Healthcare Long Short Onshore Fund LP and Altium Healthcare Long Short GP LLC jointly report beneficial ownership of 35,659 shares of Sharps Technology Inc. common stock issuable upon conversion of Series A warrants, representing 3.48% of the class based on 1,023,214 shares outstanding.

The filing notes the Series A warrants are subject to a 9.99% Warrant Blocker that prevents exercise to the extent it would raise ownership above that threshold. The cover-page figures include the full number of shares issuable on conversion and do not give effect to the Warrant Blocker, so the actual number of shares the reporting persons could beneficially own after giving effect to the blocker is less than the reported amount. Reported sole voting and dispositive power are 0, with 35,659 shared voting and dispositive power.

Positive

• Transparent disclosure of the number of shares issuable upon conversion of Series A warrants (35,659)
• Clear statement that the warrants are subject to a 9.99% Warrant Blocker, limiting potential exercise above that threshold
• Roles identified for the reporting persons (Fund as record owner; adviser and GP may be deemed beneficial owners)

Negative

• Reported share counts include full conversion and do not give effect to the Warrant Blocker, so the figures may overstate actual exercisable ownership
• Position is below 5% (3.48%), indicating limited influence over issuer governance

Insights

Financial Analyst

TL;DR: Altium discloses a passive 3.48% economic interest via warrants; reported counts include full conversion and exclude the Warrant Blocker.

The filing shows the Fund is the record owner and the adviser and GP may be deemed beneficial owners. The position is documented as 35,659 shares issuable on conversion of Series A warrants and is reported with 0 sole voting/dispositive power and 35,659 shared voting/dispositive power. The reported percentage is calculated on a base of 1,023,214 shares outstanding. Because the filing expressly states the Warrant Blocker limits actual exercisable ownership and the cover numbers do not reflect that blocker, the economic and voting impact is constrained by that contractual limit.

Corporate Governance Expert

TL;DR: Disclosure is transparent on structure and limits; ownership appears passive and constrained by a contractual blocker.

The Schedule 13G/A identifies the reporting persons and clarifies roles: the Fund as record owner, the adviser and GP as entities that may be deemed beneficial owners. The filing specifies the securities reported are warrants and that a 9.99% blocker prevents exercise beyond that threshold. Shared voting and dispositive authority is recorded at 35,659 shares with no sole control asserted. Overall this is a clear, routine disclosure of a sub-5% passive position with contractual limits on conversion.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Sharps Technology Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

82003F119

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 82003F119

1

Names of Reporting Persons

Altium Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 35,659.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 35,659.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

35,659.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.48 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: See Item 4 for a description of the infomration reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

CUSIP No. 82003F119

1

Names of Reporting Persons

Altium Healthcare Long Short Onshore Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 35,659.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 35,659.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

35,659.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.48 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: See Item 4 for a description of the infomration reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

CUSIP No. 82003F119

1

Names of Reporting Persons

Altium Healthcare Long Short GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 35,659.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 35,659.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

35,659.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.48 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: See Item 4 for a description of the infomration reported in rows (6), (8), (9) and (11).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Sharps Technology Inc.
(b)	Address of issuer's principal executive offices: 105 MAXESS ROAD, STE. 124, MELVILLE, NY, 11747
Item 2.
(a)	Name of person filing: This statement is jointly filed by and on behalf of each of Altium Healthcare Long Short Onshore Fund LP (the "Fund"), Altium Capital Management LLC, and Altium Healthcare Long Short GP LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management LLC is the investment adviser of, and may be deemed to beneficially own securities, owned by the Fund. Altium Healthcare Long Short GP LLC is the general partner of, and may be deemed to beneficially own securities, owned by the Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each of the Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the reporting persons is 152 West 57th Street, FL 20, New York, NY 10019
(c)	Citizenship: See Item 4 on the cover page(s) hereto.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 82003F119
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Pursuant to the terms of the securities purchase agreement entered into between the Fund and the Issuer, the Fund purchased Series A Warrants. The Reporting Persons are subject to a Warrant Blocker and as a result cannot exercise the Series A Warrants to the extent the Reporting Persons would beneficially own, after any such conversion or exercise, more than 9.99% of the outstanding shares of Common Stock. The Series A Warrants (the "Warrants") are subject to a 9.99% blocker (the "Warrant Blocker") which prevents the Reporting Persons from exercising the Warrants to the extent the Reporting Persons would beneficially own, after any such conversion or exercise, more than 9.99% of the outstanding shares of Common Stock. However, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such Warrants and does not give effect to the Warrant Blocker. Therefore, the actual number of shares of Common Stock beneficially owned by each such Reporting Person, after giving effect to such Warrant Blocker, is less than the number of securities reported in rows (6), (8) and (9). The securities reported in rows (6), (8) and (9) of each Cover Page are inclusive of the following: 35,659 shares of Common Stock issuable up conversion of Series A Warrants. The percentage in row (11) is based on 1,023,214 shares of Common Stock outstanding as of July 17, 2025, as set forth in the Issuer's Form DEFR14A filed with the Securities and Exchange Commission ("SEC") on August 5, 2025.
(b)	Percent of class: 3.48 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Altium Capital Management LLC

Signature:	Jacob Gottlieb
Name/Title:	CEO
Date:	08/14/2025

Altium Healthcare Long Short Onshore Fund LP

Signature:	Jacob Gottlieb
Name/Title:	Managing Member of Altium Healthcare Long Short GP LLC
Date:	08/14/2025

Altium Healthcare Long Short GP LLC

Signature:	Jacob Gottlieb
Name/Title:	Managing Member
Date:	08/14/2025

FAQ

How many shares does Altium report for Sharps Technology (STSSW)?

The reporting persons disclose 35,659 shares of common stock issuable upon conversion of Series A warrants.

What percentage of Sharps Technology (STSSW) does that represent?

The filing states this equals 3.48% of the class based on 1,023,214 shares outstanding.

Are the reported warrants subject to any exercise limits?

Yes. The Series A warrants are subject to a 9.99% Warrant Blocker that restricts exercise if ownership would exceed that threshold.

Who are the reporting persons in this Schedule 13G/A for STSSW?

The statement is jointly filed by Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC, and Altium Healthcare Long Short GP LLC.

Do the reporting persons claim sole voting or dispositive power?

No. The filing shows 0 sole voting power and 0 sole dispositive power, with 35,659 shares reported as shared voting and dispositive power.